Latest Headlines
Stereotactic radiation controls early stage lung cancer
Melanoma survivors at higher risk of other cancers
Cladribine and fludarabine equally helpful for progressive CLL
More frequent surveillance reduces colon cancer risk in Lynch syndrome families
Radiation can be avoided in early Hodgkin's lymphoma
NEWS PROVIDED BY 
VIEW ALL NEWSNovartis cancer drug wins U.S. priority review
LONDON (Reuters) - An investigational drug from Swiss drugmaker Novartis AG has been granted priority review in the United States as a treatment for advanced kidney cancer.
Novartis said on Tuesday that RAD001 or everolimus, which it plans to sell under the brand name Afinitor, had been accepted for fast review given its potential to benefit patients who fail to respond to standard therapy.
U.S. Food and Drug Administration priority review status accelerates the standard review timing from 10 to six months.
Clinical trial results released earlier this year showed that after failure of standard treatment in patients with advanced kidney cancer, RAD001 more than doubled time without tumour growth and reduced the risk of disease progression by 70%.
The new drug works by blocking the protein mTOR and disrupting the growth, division and metabolism of cancer cells.
The once-a-day pill is also being tested in other cancers including lymphoma and neuroendocrine tumours.
Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
NEWS PROVIDED BY
TEXT SIZE 